Vaxcyte (PCVX) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Vaxcyte (PCVX) over the past year, gaining 99.9% versus a gain of 70.0%. Over five years, PCVX leads with a +192.4% price change compared with +112.8% for TVTX. Vaxcyte is the larger company by market cap ($11.15 billion vs $4.91 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCVX | TVTX |
|---|---|---|
| Share price | $71.38 | $52.13 |
| Market cap | $11.15B | $4.91B |
| 1-day change | +9.79% | +0.16% |
| YTD return | +54.70% | +36.42% |
| 1-year return | +69.99% | +99.94% |
| 5-year return | +192.42% | +112.76% |
| Forward P/E | — | 9.24 |
| EPS (TTM) | $-8.36 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | $-766.63M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $90.75 | $68.73 |
| 52-week low | $39.87 | $22.59 |
| Distance from 52-week high | -21.34% | -24.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.91% | +44.29% |
| Average volume | 1.76M | 1.59M |
| Shares outstanding | 156.22M | 94.26M |
| Employees | 507 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vaxcyte is about 2.3 times larger than Travere Therapeutics by market value ($11.15B vs $4.91B).
- TVTX has outperformed PCVX by 29.9 percentage points over the past year.
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
PCVX vs TVTX FAQ
Which is bigger, Vaxcyte or Travere Therapeutics?
Vaxcyte (PCVX) is larger, with a market capitalization of $11.15B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, PCVX or TVTX?
TVTX returned +99.94% over the past 12 months, compared with +69.99% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Vaxcyte and Travere Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Vaxcyte and Biotechnology: Pharmaceutical Preparations for Travere Therapeutics.